XML 92 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Events (Notes)
3 Months Ended
Dec. 31, 2019
Subsequent Event [Line Items]  
Subsequent Events [Text Block]
NOTE 17—SUBSEQUENT EVENTS

Contingent Consideration

In November 2019, the Company received new regulatory information and now expects to achieve an additional $10.0 million contingent regulatory milestone related to the MyoScience Acquisition, which can be made in either cash or shares of the Company’s common stock, or a combination thereof, at the election of MyoScience shareholders. As a result, in the fourth quarter of 2019, the Company expects to record a charge to acquisition-related charges of approximately $9.0 million. For more information regarding contingent milestone payments related to the MyoScience Acquisition, refer to Note 4, MyoScience Acquisition.